A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results

被引：0

作者：

Cortes, Jorge E. ^{[1
]}

Perl, Alexander E. ^{[2
]}

Smith, Catherine C. ^{[3
]}

Kovacsovics, Tibor ^{[4
]}

Dombret, Herve ^{[5
]}

Dohner, Hartmut ^{[6
]}

Steffen, Bjorn ^{[7
]}

Pigneux, Arnaud ^{[8
]}

Rousselot, Philippe ^{[9
]}

Krauter, Juergen ^{[10
]}

Martinelli, Giovanni ^{[11
]}

Estey, Elihu H. ^{[12
]}

Burnett, Alan K. ^{[13
]}

Ho, Anthony D. ^{[14
]}

Ifrah, Norbert ^{[15
]}

de Witt, Theo ^{[16
]}

Corringham, Robert ^{[17
]}

James, Joyce ^{[17
]}

Lilienfeld, David ^{[17
]}

Leo, Eugen ^{[17
]}

Gammon, Guy ^{[17
]}

Levis, Mark J. ^{[18
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[3] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA USA

[4] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[5] Univ Paris 07, Hop St Louis, AP HP, EA 3518, Paris, France

[6] Univ Ulm, Dept Internal Med 3, D-7900 Ulm, Germany

[7] Klinikum JW Goethe Univ Frankfurt Main, Frankfurt, Germany

[8] CHU Bordeaux, Pessac, France

[9] Univ Versailles St Quentin Yvelines, Hop Versailles, Le Chesnay, France

[10] Hannover Med Sch, D-3000 Hannover, Germany

[11] Univ Bologna, Sch Med, Seragnoli Inst Hematol, Bologna, Italy

[12] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA

[13] Cardiff Univ, Sch Med, Cardiff, S Glam, Wales

[14] Univ Heidelberg, Dept Hematol & Oncol, Heidelberg, Germany

[15] CHU Angers, Serv Hematol, Angers, France

[16] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands

[17] Ambit Biosci, San Diego, CA USA

[18] Johns Hopkins Univ, Div Hematol Malignancies, Dept Oncol, Baltimore, MD USA

来源：

BLOOD | 2011年 / 118卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1105 / 1105

页数：1

共 50 条

[21] Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Cortes, Jorge E.
Khaled, Samer
Martinelli, Giovanni
Perl, Alexander E.
Ganguly, Siddhartha
Russell, Nigel
Kraemer, Alwin
Dombret, Herve
Hogge, Donna
Jonas, Brian A.
Leung, Anskar Yu-Hung
Mehta, Priyanka
Montesinos, Pau
Radsak, Markus
Sica, Simona
Arunachalam, Meena
Holmes, Melissa
Kobayashi, Ken
Namuyinga, Ruth
Ge, Nanxiang
Yver, Antoine
Zhang, Yufen
Levis, Mark J.
LANCET ONCOLOGY, 2019, 20 (07): : 984 - 997
[22] Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
Daver, Naval
Garcia-Manero, Guillermo
Basu, Sreyashi
Boddu, Prajwal C.
Alfayez, Mansour
Cortes, Jorge E.
Konopleva, Marina
Ravandi-Kashani, Farhad
Jabbour, Elias
Kadia, Tapan
Nogueras-Gonzalez, Graciela M.
Ning, Jing
Pemmaraju, Naveen
DiNardo, Courtney D.
Andreeff, Michael
Pierce, Sherry A.
Gordon, Tauna
Kornblau, Steven M.
Flores, Wilmer
Alhamal, Zainab
Bueso-Ramos, Carlos
Jorgensen, Jeffrey L.
Patel, Keyur P.
Blando, Jorge
Allison, James P.
Sharma, Padmanee
Kantarjian, Hagop
CANCER DISCOVERY, 2019, 9 (03) : 370 - 383
[23] A phase II, open-label study of clofarabine in pediatric patients with refractory or relapsed acute myelogenous leukemia.
Jeha, S
Steinherz, P
Gaynon, P
Rheingold, S
Razzouk, B
Ritchey, AK
Altman, A
Albano, E
Stine, K
Chan, KW
Weiss, J
Craig, A
Arceci, RJ
BLOOD, 2003, 102 (11) : 617A - 617A
[24] A phase II, open-label study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
Jeha, S
Gaynon, P
Steinherz, P
Kadota, R
Bomgaars, L
Razzouk, B
Luchtman-Jones, L
Altman, A
Rheingold, S
Ritchey, AK
Shen, V
Weiss, J
Chan, KW
Craig, A
Arceci, RJ
BLOOD, 2003, 102 (11) : 881A - 881A
[25] Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 study
Yu, Sijian
Zhang, Yu
Yu, Guopan
Wang, Yu
Shao, Ruoyang
Du, Xin
Xu, Na
Lin, Dongjun
Zhao, Weihua
Zhang, Xiong
Xiao, Jie
Sun, Zhiqiang
Deng, Lan
Liang, Xinquan
Zhang, Hongyu
Guo, Ziwen
Dai, Min
Shi, Pengcheng
Huang, Fen
Fan, Zhiping
Liu, Qiong
Lin, Ren
Jiang, Xuejie
Xuan, Li
Liu, Qifa
Jin, Hua
JOURNAL OF INTERNAL MEDICINE, 2024, 295 (02) : 216 - 228
[26] An open-label, randomized phase III study of gilteritinib versus salvage chemotherapy in relapsed or refractory FLT3 mutation-positive acute myeloid leukemia.
Perl, Alexander E.
Cortes, Jorge E.
Strickland, Stephen Anthony
Ritchie, Ellen K.
Neubauer, Andreas
Martinelli, Giovanni
Naoe, Tomoki
Pigneux, Arnaud
Rousselot, Philippe H.
Rollig, Christoph
Baer, Maria R.
Larson, Richard A.
James, Angela Joubert
Chen, Caroline
Shu, Lei
Hasabou, Nahla
Bahceci, Erkut
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[27] Sorafenib Plus Triplet Therapy with Venetoclax, Azacitibine and Homoharringtonine for Refractory/Relapsed Acute Myeloid Leukemia with FLT3-ITD: A Multicentre, Phase 2 Study
Yu, Sijian
Liu, Qifa
Zhang, Yu
Yu, Guopan
Wang, Yu
Shao, Ruoyang
Liu, Qiong
BLOOD, 2023, 142
[28] Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study
Usuki, Kensuke
Sakura, Toru
Kobayashi, Yukio
Miyamoto, Toshihiro
Iida, Hiroatsu
Morita, Satoshi
Bahceci, Erkut
Kaneko, Masahito
Kusano, Mikiko
Yamada, Shunsuke
Takeshita, Shigeru
Miyawaki, Shuichi
Naoe, Tomoki
CANCER SCIENCE, 2018, 109 (10): : 3235 - 3244
[29] A phase I study of milademetan in combination with quizartinib in patients (pts) with newly diagnosed (ND) or relapsed/refractory (RR) FLT3-ITD acute myeloid leukemia (AML).
Daver, Naval Guastad
Zhang, Weiguo
Graydon, Richard
Dawra, Vikas
Xie, Jingdong
Kumar, Prasanna
Andreeff, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[30] A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML)
Daver, Naval G.
Zhang, Weiguo
Graydon, Richard
Dawra, Vikas K.
Xie, Jingdong
Kumar, Prasanna
Andreeff, Michael
BLOOD, 2019, 134

← 1 2 3 4 5 →